Post by AZAFAROS B.V.

AZAFAROS B.V. has further strengthened its leadership team with the appointment of Amy Sullivan as Chief Financial Officer. Ms. Sullivan is an experienced biotech finance leader with over 30 years’ experience in capital markets and strategy and a proven track record in fundraising, M&A and company transformation. “Amy’s expertise in financing, strategic positioning and transaction execution will be instrumental as we advance our Phase 3 studies with nizubaglustat and continue to build Azafaros as we prepare to file for drug marketing authorization and launch in GM1/GM2 and NPC,” said Azafaros CEO, Stefano Portolano, MD. Read the fulll story here: https://lnkd.in/eXCKVP7s #Innovatation, #Biotech, #Finance, #drugdevelopment, #RareDiseases, #GM1, #GM2, #NPC,